| pubmed-article:17183068 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17183068 | lifeskim:mentions | umls-concept:C0033325 | lld:lifeskim |
| pubmed-article:17183068 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:17183068 | lifeskim:mentions | umls-concept:C0279626 | lld:lifeskim |
| pubmed-article:17183068 | lifeskim:mentions | umls-concept:C0140080 | lld:lifeskim |
| pubmed-article:17183068 | lifeskim:mentions | umls-concept:C0005516 | lld:lifeskim |
| pubmed-article:17183068 | lifeskim:mentions | umls-concept:C0302350 | lld:lifeskim |
| pubmed-article:17183068 | lifeskim:mentions | umls-concept:C1521840 | lld:lifeskim |
| pubmed-article:17183068 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:17183068 | pubmed:dateCreated | 2007-4-26 | lld:pubmed |
| pubmed-article:17183068 | pubmed:abstractText | Insulin-like growth factor (IGF)-I receptor (IGF-Ir) signaling is required for tumorigenicity and progression of many tumors but this pathway has not been well studied as a prognostic factor or potential therapeutic target in esophageal squamous cell carcinoma (ESCC). In this paper, the association between the expression of IGF-Ir and IGF-II ligand and prognosis was investigated immunohistochemically in 100 surgically resected ESCC. We then assessed the therapeutic effect of blocking IGF receptor signaling using dominant negative IGF-Ir (IGF-Ir/dn) in ESCC in vitro. Expression of IGF-Ir and IGF-II were detected in 60 and 50% of tumors, respectively, and were associated with invasion depth, metastasis, advanced tumor stage and recurrence. Patients with tumors expressing both IGF-Ir and IGF-II had a significantly shorter survival than those expressing either alone or neither in both single and multivariate analysis. IGF-Ir/dn suppressed proliferation and motility as well as upregulating chemotherapy-induced apoptosis through blocking ligand-induced Akt activation. We propose that detection of IGF-Ir/IGF-II in ESCC may be useful for the prediction of recurrence and poor prognosis and for selecting patients for IGF-Ir-targeted therapy. Therapeutic blockade of IGF-Ir may be a useful anticancer therapeutic for ESCC. | lld:pubmed |
| pubmed-article:17183068 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17183068 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17183068 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17183068 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17183068 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17183068 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17183068 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17183068 | pubmed:month | May | lld:pubmed |
| pubmed-article:17183068 | pubmed:issn | 0143-3334 | lld:pubmed |
| pubmed-article:17183068 | pubmed:author | pubmed-author:TranJ VJV | lld:pubmed |
| pubmed-article:17183068 | pubmed:author | pubmed-author:ImaiKohzohK | lld:pubmed |
| pubmed-article:17183068 | pubmed:author | pubmed-author:WangYuY | lld:pubmed |
| pubmed-article:17183068 | pubmed:author | pubmed-author:YamamotoHiroy... | lld:pubmed |
| pubmed-article:17183068 | pubmed:author | pubmed-author:HosokawaMasao... | lld:pubmed |
| pubmed-article:17183068 | pubmed:author | pubmed-author:MinYongfenY | lld:pubmed |
| pubmed-article:17183068 | pubmed:author | pubmed-author:ImsumranArisa... | lld:pubmed |
| pubmed-article:17183068 | pubmed:author | pubmed-author:CarboneDavid... | lld:pubmed |
| pubmed-article:17183068 | pubmed:author | pubmed-author:AdachiYasushi... | lld:pubmed |
| pubmed-article:17183068 | pubmed:author | pubmed-author:ShinomuraYasu... | lld:pubmed |
| pubmed-article:17183068 | pubmed:author | pubmed-author:ArimuraYoshia... | lld:pubmed |
| pubmed-article:17183068 | pubmed:author | pubmed-author:LeeChoon-Taek... | lld:pubmed |
| pubmed-article:17183068 | pubmed:author | pubmed-author:NoshoKatsuhik... | lld:pubmed |
| pubmed-article:17183068 | pubmed:author | pubmed-author:PiaoWenhuaW | lld:pubmed |
| pubmed-article:17183068 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17183068 | pubmed:volume | 28 | lld:pubmed |
| pubmed-article:17183068 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17183068 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17183068 | pubmed:pagination | 947-56 | lld:pubmed |
| pubmed-article:17183068 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:17183068 | pubmed:meshHeading | pubmed-meshheading:17183068... | lld:pubmed |
| pubmed-article:17183068 | pubmed:meshHeading | pubmed-meshheading:17183068... | lld:pubmed |
| pubmed-article:17183068 | pubmed:meshHeading | pubmed-meshheading:17183068... | lld:pubmed |
| pubmed-article:17183068 | pubmed:meshHeading | pubmed-meshheading:17183068... | lld:pubmed |
| pubmed-article:17183068 | pubmed:meshHeading | pubmed-meshheading:17183068... | lld:pubmed |
| pubmed-article:17183068 | pubmed:meshHeading | pubmed-meshheading:17183068... | lld:pubmed |
| pubmed-article:17183068 | pubmed:meshHeading | pubmed-meshheading:17183068... | lld:pubmed |
| pubmed-article:17183068 | pubmed:meshHeading | pubmed-meshheading:17183068... | lld:pubmed |
| pubmed-article:17183068 | pubmed:meshHeading | pubmed-meshheading:17183068... | lld:pubmed |
| pubmed-article:17183068 | pubmed:meshHeading | pubmed-meshheading:17183068... | lld:pubmed |
| pubmed-article:17183068 | pubmed:meshHeading | pubmed-meshheading:17183068... | lld:pubmed |
| pubmed-article:17183068 | pubmed:meshHeading | pubmed-meshheading:17183068... | lld:pubmed |
| pubmed-article:17183068 | pubmed:meshHeading | pubmed-meshheading:17183068... | lld:pubmed |
| pubmed-article:17183068 | pubmed:meshHeading | pubmed-meshheading:17183068... | lld:pubmed |
| pubmed-article:17183068 | pubmed:meshHeading | pubmed-meshheading:17183068... | lld:pubmed |
| pubmed-article:17183068 | pubmed:meshHeading | pubmed-meshheading:17183068... | lld:pubmed |
| pubmed-article:17183068 | pubmed:meshHeading | pubmed-meshheading:17183068... | lld:pubmed |
| pubmed-article:17183068 | pubmed:meshHeading | pubmed-meshheading:17183068... | lld:pubmed |
| pubmed-article:17183068 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17183068 | pubmed:articleTitle | Insulin-like growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma. | lld:pubmed |
| pubmed-article:17183068 | pubmed:affiliation | First Department of Internal Medicine, Sapporo Medical University, South-1, West-16, Chuo-ku, Sapporo 060-8543, Japan. | lld:pubmed |
| pubmed-article:17183068 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17183068 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17183068 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17183068 | lld:pubmed |
